Literature DB >> 12166582

Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis.

M Humbert1, P Labrune, O Sitbon, C Le Gall, J Callebert, P Hervé, D Samuel, R Machado, R Trembath, L Drouet, J M Launay, G Simonneau.   

Abstract

A case of pulmonary arterial hypertension in a patient with type-Ia glycogen-storage disease, a rare autosomal recessive disorder caused by a deficiency of glucose-6-phosphatase is reported in this study. It has been suggested that the occurrence of pulmonary arterial hypertension in type-Ia glycogen-storage disease could be due to an abnormal production of vasoconstrictive amines such as serotonin. To test this hypothesis, plasma serotonin concentrations were prospectively measured in 13 patients with type-Ia glycogen-storage disease, one patient with severe pulmonary hypertension and type-Ia glycogen-storage disease, 16 patients displaying severe pulmonary arterial hypertension, and 26 normal healthy controls. Elevated plasma serotonin concentrations were found in patients with either severe pulmonary arterial hypertension (38.8+/-7.3 nmol x L(-1)) or type-Ia glycogen-storage disease (36.8+/-11.5 nmol x L(-1)), as compared with controls (8.8+/-0.6 nmol x L(-1), p<0.001). Plasma serotonin was dramatically elevated in the patient with type-Ia glycogen-storage disease and pulmonary arterial hypertension (113.4 nmol x L(-1)). It is concluded that type-Ia glycogen-storage disease may be another condition in which abnormal handling of serotonin is one event in a multistep process leading to severe pulmonary arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12166582     DOI: 10.1183/09031936.02.00258702

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

1.  Two Cases of Pulmonary Hypertension Associated with Type III Glycogen Storage Disease.

Authors:  Teresa M Lee; Erika S Berman-Rosenzweig; Alfred E Slonim; Wendy K Chung
Journal:  JIMD Rep       Date:  2011-06-22

Review 2.  Medical Management of Pulmonary Hypertension with Unclear and/or Multifactorial Mechanisms (Group 5): Is There a Role for Pulmonary Arterial Hypertension Medications?

Authors:  Jason Weatherald; Laurent Savale; Marc Humbert
Journal:  Curr Hypertens Rep       Date:  2017-10-18       Impact factor: 5.369

3.  Acute psychosis in glycogen storage disease: a rare but severe complication.

Authors:  Thomas Frederick Dunne; Tarekegn Geberhiwot; Rowena Jones
Journal:  BMJ Case Rep       Date:  2019-07-04

4.  Plasma and platelet serotonin levels in patients with liver cirrhosis.

Authors:  Dorde M Culafic; Dusko S Mirkovic; Miodrag D Vukcevic; Jelena S Rudic
Journal:  World J Gastroenterol       Date:  2007-11-21       Impact factor: 5.742

5.  Glycogen Storage Disease type 1a - a secondary cause for hyperlipidemia: report of five cases.

Authors:  Patrícia Margarida Serra Carvalho; Nuno José Marques Mendes Silva; Patrícia Glória Dinis Dias; João Filipe Cordeiro Porto; Lèlita Conceição Santos; José Manuel Nascimento Costa
Journal:  J Diabetes Metab Disord       Date:  2013-06-06

Review 6.  Glucose-6-phosphatase deficiency.

Authors:  Roseline Froissart; Monique Piraud; Alix Mollet Boudjemline; Christine Vianey-Saban; François Petit; Aurélie Hubert-Buron; Pascale Trioche Eberschweiler; Vincent Gajdos; Philippe Labrune
Journal:  Orphanet J Rare Dis       Date:  2011-05-20       Impact factor: 4.123

Review 7.  Pulmonary arterial hypertension.

Authors:  David Montani; Sven Günther; Peter Dorfmüller; Frédéric Perros; Barbara Girerd; Gilles Garcia; Xavier Jaïs; Laurent Savale; Elise Artaud-Macari; Laura C Price; Marc Humbert; Gérald Simonneau; Olivier Sitbon
Journal:  Orphanet J Rare Dis       Date:  2013-07-06       Impact factor: 4.123

8.  5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure.

Authors:  Wiebke Janssen; Yves Schymura; Tatyana Novoyatleva; Baktybek Kojonazarov; Mario Boehm; Astrid Wietelmann; Himal Luitel; Kirsten Murmann; Damian Richard Krompiec; Aleksandra Tretyn; Soni Savai Pullamsetti; Norbert Weissmann; Werner Seeger; Hossein Ardeschir Ghofrani; Ralph Theo Schermuly
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

9.  A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2).

Authors:  Howard M Lazarus; Jill Denning; Stephen Wring; Michelle Palacios; Sidra Hoffman; Katelyn Crizer; Watiri Kamau-Kelley; William Symonds; Jeremy Feldman
Journal:  Pulm Circ       Date:  2022-05-11       Impact factor: 2.886

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.